Multiproxy paleodietary reconstruction using stable isotopes and starch analysis: the case of the archaeological site of Playa del Mango, Granma, Cuba

Paleoethnobotanical and stable isotope studies have demonstrated that the indigenous groups that populated the Antilles, traditionally understood as dependent exclusively on wild resources, cultivated and consumed both C3 and C4 plants even before the arrival of the ceramic-bearing Arawak groups. However, the relative importance of cultigens and the differential use of plants, especially maize, between populations and individuals remains un-known. In this paper we combined the analysis of stable isotopes (delta 15N, delta 13Cco, delta 13Cen, delta 13Cap, delta 34S) of 27 in-dividuals from the archaeological site of Playa del Mango, Cuba with the identification of starch grains in dental calculus. The stable isotope results indicate that the sampled population had a 70:30 C3/C4 diet, where at least 65 % was based on C3 protein. Starches from C3 (e.g., Marantaceae, Ipomoea batatas) and C4 plants (Zea mays) were found in similar proportions (50:50). These results support that the lack or abundance of starch grains cannot be used to infer directly the frequency at which C3 and C4 plants were consumed within a small popu-lation. Statistically significant differences between females and males in the carbon isotope composition of diet, and its energy portion, suggests a differential consumption of plants by sex. Playa del Mango individual diets were statistically different from those of coeval sites, supporting our previous findings that groups with different dietary traditions concurrently inhabited Cuba in precolonial times. The study demonstrates the power of combined use of stable isotope models, and starch analysis, to provide a more nuanced reconstruction of dietary practices in past human populations.Archaeological science

Tracking breastfeeding and weaning practices in ancient populations by combining carbon, nitrogen and oxygen stable isotopes from multiple non-adult tissues

This paper explores the potential of combining different isotope systems from different tissues to improve resolution when reconstructing breastfeeding and weaning practices (BWP) in archaeology. Additionally, we tested whether changes in diet can be detected in deciduous teeth. Rib collagen samples from 22 infants/children from the archaeological site of Bacuranao I (Mayabeque, Cuba) were processed for nitrogen (delta N-15) and carbon (delta C-13(co)) stable isotopes and assessed using a Bayesian model (WARN). In addition, enamel of 48 teeth from 30 infants/children were analyzed for oxygen (delta O-18(en)) and carbon (delta C-13(en)) stable isotopes. Data revealed that the timing of weaning cannot be characterized precisely by analyzing either delta O-18 or delta N-15. While a depletion in both delta N-15 and delta C-13(co) is only evident after one year, the WARN model suggested that the weaning process started at around 3 months and ended around 1.7 years. Most teeth were enriched in delta O-18(en) compared to deciduous incisors, suggesting a breastfeeding signal. However, a high variability in delta O-18 was found between similar teeth from the same individuals. Higher enrichment in delta O-18(en), and variability, was observed in tissues formed during the first six months of life. A delta C-13 enrichment of 1.0% was observed among deciduous teeth and ribs. While most individuals enriched in delta N-15 showed enrichment in delta C-13, the delta O-18 values were more variable. Our data suggests that stable isotopes of deciduous teeth, especially delta C-13(en), can be used to detect changes in diet during the weaning process. It is also possible that the delta O-18 enrichment observed in M1 is influenced by the effects of cooking techniques on weaning foods. The combination of multiple isotope systems and tissues overcome some of the limitations posed by single tissue approaches.Archaeological science

Antiinflammatory therapy with canakinumab for atherosclerotic disease

BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. METHODS: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). CONCLUSIONS: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. Copyright © 2017 Massachusetts Medical Society